Numinus Wellness Inc., a prominent leader in the realm of psychedelics-focused mental healthcare, has officially declared its intent to acquire MedBright AI Investments Inc. This strategic maneuver is part of a larger reorganization effort aimed at achieving positive EBITDA in the near future.
The proposed acquisition is positioned to unite Numinus’ proficiency in drug-assisted mental health treatment with MedBright’s AI technology, tailored to improve healthcare accessibility, reduce costs, and enhance patient outcomes. According to the terms of the agreement, Numinus will issue approximately 204,729,372 of its shares, equating to approximately 39% ownership of the pro forma company on an undiluted basis.
In addition to the acquisition, Numinus intends to rebrand as Numinus Intelligence upon the conclusion of the transaction, while retaining the company’s ticker symbol as NUMI on the Toronto Stock Exchange.
It is anticipated that the strategic amalgamation of MedBright’s AI-enabled clinical solution capabilities and Numinus’ extensive experience in drug-assisted mental health treatment will notably enhance clinical operations and capitalize on reimbursable offerings. Numinus looks to leverage its expertise in traditional therapy, clinic management, patient care, insurance reimbursement, and psychedelic-assisted therapy to establish a distinctive AI-enabled offering for mental health care providers in the U.S.
Upon finalization of the transaction, Numinus will fortify its financial position with over $5 million in cash and liquid securities. The operational team is also dedicated to reducing overhead and enacting a revenue improvement strategy for its Utah clinics.
Following the acquisition, seasoned leaders from the MedBright AI team will integrate into Numinus’ management team and Board. Numinus’ CEO, Payton Nyquvest, has confidently expressed his belief in the synergy between the two companies, affirming, “We believe that harnessing our expertise and intellectual property to complement MedBright’s AI technology will amplify our ability to help those in need of care while driving revenue growth and, importantly, profitability.”
Undoubtedly, this strategic acquisition signifies a significant leap forward for Numinus Wellness in its mission to enhance mental healthcare through the integration of AI technology. Expected to enhance not only the company’s operational and financial performance, this move is also poised to contribute to the broader advancement of mental health treatment.
In summary, Numinus Wellness’ acquisition of MedBright AI Investments Inc. marks a pivotal milestone in the company’s strategic growth plan. By harnessing AI technology and merging it with its existing expertise in mental health treatment, Numinus is positioned to make significant advancements in improving patient care and achieving sustainable profitability.
Source:
Benzinga.com